Literature DB >> 19915482

Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population.

Thomas Sehestedt1, Jørgen Jeppesen, Tine W Hansen, Susanne Rasmussen, Kristian Wachtell, Hans Ibsen, Christian Torp-Pedersen, Michael H Olsen.   

Abstract

OBJECTIVE: The risk chart from the European Society of Hypertension (ESH) and Systemic Coronary Risk Evaluation (SCORE) from the European Society of Cardiology (ESC) are equally recommended tools for risk stratification. However, ESH risk chart recommends measuring subclinical organ damage, whereas SCORE is based on traditional risk factors. We wanted to compare the predictive performance of the two charts.
METHODS: In a Danish population sample of 1344 individuals aged 41, 51, 61 and 71 years without known diabetes, prior stroke or myocardial infarction, not receiving cardiovascular, antidiabetic or lipid-lowering medications and with higher than optimal blood pressure (> or =120/80 mmHg), we measured traditional risk factors and subclinical organ damage. The endpoints were cardiovascular death and a composite of cardiovascular death, nonfatal myocardial infarction and stroke (CEP).
RESULTS: During the following 12.8 years cardiovascular death and CEP occurred in 71 and 132 patients, respectively. Forty-two percent had unrecognized hypertension. The sizes and characteristics of the populations in the different risk categories of the charts varied considerably as ESH risk chart allocated 368 patients to higher-risk categories than SCORE (P < 0.001). These patients were younger, with higher blood pressure and less frequently male smokers. However, ESH risk chart agreed with ESC guidelines for antihypertensive treatment using SCORE in 89% (634/713) of the patients recommended treatment and produced similar sensitivities (79 vs. 79%), specificities (46 vs. 50%), positive (14 vs. 15%) and negative (95 vs. 96%) predictive values for CEP.
CONCLUSION: Although SCORE did not use subclinical organ damage, the guidelines by ESH and ESC using SCORE recommended antihypertensive treatment in almost the same patients.

Entities:  

Mesh:

Year:  2009        PMID: 19915482     DOI: 10.1097/HJH.0b013e328330e90a

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

1.  Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: a single biopsy cohort analysis.

Authors:  C De Nunzio; G Truscelli; A Trucchi; S Petta; M Tubaro; M Gacci; C Gaudio; F Presicce; A Tubaro
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-06       Impact factor: 5.554

2.  Validation of Central and Peripheral Non-Invasive Hemodynamic Variables Using an Oscillometric Method.

Authors:  Darío Echeverri; Alejandro Pizano; Jaime Cabrales; Karen Moreno
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-10-28

Review 3.  Imaging Subclinical Atherosclerosis: Where Do We Stand?

Authors:  Nikolaos Papageorgiou; Alexandros Briasoulis; Emmanuel Androulakis; Dimitris Tousoulis
Journal:  Curr Cardiol Rev       Date:  2017

Review 4.  Cardiovascular Risk Prediction Models and Scores in the Era of Personalized Medicine.

Authors:  Areti Sofogianni; Nikolaos Stalikas; Christina Antza; Konstantinos Tziomalos
Journal:  J Pers Med       Date:  2022-07-20

5.  Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings.

Authors:  Pietro A Modesti; Piergiuseppe Agostoni; Charles Agyemang; Sanjay Basu; Athanase Benetos; Francesco P Cappuccio; Antonio Ceriello; Stefano Del Prato; Robert Kalyesubula; Eoin O'Brien; Michael O Kilama; Stefano Perlini; Eugenio Picano; Gianpaolo Reboldi; Giuseppe Remuzzi; David Stuckler; Marc Twagirumukiza; Luc M Van Bortel; Ghassan Watfa; Dong Zhao; Gianfranco Parati
Journal:  J Hypertens       Date:  2014-05       Impact factor: 4.844

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.